Barinthus Biotherapeutics (BRNS) News Today $1.28 +0.05 (+4.07%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 3, 2024 | marketbeat.com1,513,644 Shares in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Purchased by Alphabet Inc.Alphabet Inc. bought a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,513,644 shares of the companyAugust 29, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Decline in Short InterestBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 9,700 shares, a decrease of 34.5% from the July 31st total of 14,800 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 23,800 shares, the short-interest ratio is currently 0.4 days.August 15, 2024 | marketbeat.comResearch Analysts Offer Predictions for Barinthus Biotherapeutics plc's Q3 2024 Earnings (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Investment analysts at HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Barinthus Biotherapeutics in a research note issued on Monday, August 12th. HC Wainwright analyst Y. Chen now expects that the company willAugust 13, 2024 | marketbeat.comM&G Plc Invests $7.28 Million in Barinthus Biotherapeutics plc (NASDAQ:BRNS)M&G Plc bought a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,197,349 shares of the company's stock, vAugust 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $9.50 Price Target at Alliance Global PartnersAlliance Global Partners reduced their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating for the company in a research note on Tuesday.August 11, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSBarinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.01).August 8, 2024 | stockhouse.comBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial ResultsJuly 25, 2024 | marketbeat.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Increases By 223.9%Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 29,800 shares, an increase of 223.9% from the June 30th total of 9,200 shares. Based on an average trading volume of 24,300 shares, the short-interest ratio is presently 1.2 days. Currently, 0.1% of the company's shares are sold short.July 24, 2024 | finance.yahoo.comHere's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn SituationJune 30, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Increase in Short InterestBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 7,200 shares, an increase of 24.1% from the May 31st total of 5,800 shares. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the company's stock are sold short.June 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by William BlairWilliam Blair reissued an "outperform" rating on shares of Barinthus Biotherapeutics in a research note on Thursday.June 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $3.00 Price Target at BarclaysBarclays reduced their price objective on Barinthus Biotherapeutics from $7.00 to $3.00 and set an "overweight" rating on the stock in a research note on Thursday.June 12, 2024 | globenewswire.comBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsJune 6, 2024 | globenewswire.comBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BMay 29, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 52.1% in MayBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 9,100 shares, a decrease of 52.1% from the April 30th total of 19,000 shares. Based on an average daily trading volume, of 22,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the company's shares are short sold.May 16, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Barinthus Biotherapeutics in a report on Thursday.May 16, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Barinthus Biotherapeutics plc Issued By William Blair (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Equities research analysts at William Blair raised their Q2 2024 earnings per share (EPS) estimates for Barinthus Biotherapeutics in a report issued on Monday, May 13th. William Blair analyst A. Hsieh now forecasts that the company willMay 13, 2024 | investorplace.comBRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024May 13, 2024 | globenewswire.comBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsMay 4, 2024 | finance.yahoo.comIncreases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)May 1, 2024 | globenewswire.comBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerApril 27, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 39.6% in AprilBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 14,100 shares, an increase of 39.6% from the March 31st total of 10,100 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 22,000 shares, the short-interest ratio is currently 0.6 days.April 19, 2024 | markets.businessinsider.comInfection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed PerspectivesApril 18, 2024 | globenewswire.comBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsApril 14, 2024 | marketbeat.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 15.1%Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 10,100 shares, a decrease of 15.1% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company's stock are short sold.April 14, 2024 | seekingalpha.comBRNS Barinthus Biotherapeutics plcMarch 22, 2024 | finance.yahoo.comBarinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023March 22, 2024 | marketbeat.comWilliam Blair Comments on Barinthus Biotherapeutics plc's Q1 2025 Earnings (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - William Blair issued their Q1 2025 EPS estimates for shares of Barinthus Biotherapeutics in a report released on Wednesday, March 20th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.71) forMarch 21, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $8.00 Price Target at HC WainwrightHC Wainwright decreased their target price on shares of Barinthus Biotherapeutics from $15.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday.March 20, 2024 | benzinga.comBarinthus Biotherapeutics: Q4 Earnings InsightsMarch 20, 2024 | globenewswire.comBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsMarch 4, 2024 | finance.yahoo.comIndividual investors account for 48% of Barinthus Biotherapeutics plc's (NASDAQ:BRNS) ownership, while institutions account for 25%February 25, 2024 | benzinga.comBarinthus Biotherapeutics Stock (NASDAQ:BRNS) Dividends: History, Yield and DatesFebruary 23, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Shares Up 3.1%Barinthus Biotherapeutics (NASDAQ:BRNS) Stock Price Up 3.1%January 10, 2024 | marketbeat.comBarinthus Biotherapeutics plc to Post FY2023 Earnings of ($2.03) Per Share, HC Wainwright Forecasts (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Stock analysts at HC Wainwright boosted their FY2023 earnings per share (EPS) estimates for shares of Barinthus Biotherapeutics in a research report issued on Monday, January 8th. HC Wainwright analyst Y. Chen now forecasts that the compJanuary 8, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Earns "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of Barinthus Biotherapeutics in a research report on Monday.November 7, 2023 | marketbeat.comTrading was temporarily halted for "BRNS" at 10:11 AM with a stated reason of "LULD pause." Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden’s Capital Gains Tax to Devastate Savings! (Ad)Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security. >> Get Your FREE Wealth Protection Guide << BRNS Media Mentions By Week BRNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRNS News Sentiment▼1.760.55▲Average Medical News Sentiment BRNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRNS Articles This Week▼10▲BRNS Articles Average Week Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TNYA News Today XBIT News Today OGI News Today IPHA News Today CADL News Today OTLK News Today RZLT News Today OPT News Today MRSN News Today ATOS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BRNS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.